SCHEMBL23347386

SCHEMBL23347386

CCCCCCCC(CCCCCCC)n1cnc2c(N)nc(C)nc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADA P00813 6/20 0.49
PDE2A O00408 3/20 0.49
CYP3A4 P08684 2/20 0.49
PDE4A P27815 1/20 0.49
PDE4B Q07343 1/20 0.49
PDE4C Q08493 1/20 0.49
PDE4D Q08499 1/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP1A2 P05177 1/20 0.49
ALOX15 P16050 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TSHR P16473 1/20 0.49
HIF1A Q16665 1/20 0.49
LMNA P02545 1/20 0.48
BLM P54132 1/20 0.48
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNE1 P24864 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23561539 1.00 ADA (0.49) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL22106710 0.88 ADA (0.51) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL19661763 0.88 CDK1 (0.58) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL18649621 0.88 CDK1 (0.58) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL21078562 0.86 ADA (0.48) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL22166097 0.84 ADA (0.46) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL19661690 0.84 ADA (0.46) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL21945758 0.81 ADA (0.71) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL24971291 0.81 ADA (0.71) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL22106688 0.81 ADA (0.71) ADAPDE2ACYP3A4PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11338041-B2 Exon skipping oligomer conjugates for muscular dystrophy SAREPTA THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-20210187003-A1 EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY SAREPTA THERAPEUTICS, INC. 2021-06-24 US disclosed
US-20210138079-A1 EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY SAREPTA THERAPEUTICS, INC. (US) 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11338041-B2 Exon skipping oligomer conjugates for muscular dystrophy SMN1; SMN2, UTRN, RBM17 ADA 1642/4885PDE2A 3754/4885CYP3A4 4429/4885
US-20210138079-A1 EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY SMN1; SMN2, UTRN, RBM17 ADA 1642/4885PDE2A 3754/4885CYP3A4 4429/4885
US-20210187003-A1 EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY RBM17, UTRN, UPF1 ADA 2500/4885PDE2A 3494/4885CYP3A4 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.